NEW YORK – Johnson & Johnson said Wednesday that it is reorganizing its consumer business, including giving more attention to its McNeil Consumer Healthcare unit, which has been stung by about 20 recalls of popular over-the-counter products such as Tylenol, Motrin, Rolaids and Benadryl.

The company said the consumer businesses will be organized into North America, Latin America, Asia-Pacific, and Europe-Middle East-Africa. The changes will take effect April 4.

The U.S. over-the-counter drug business will constitute yet another organization so that Johnson & Johnson can focus on McNeil, which had been part of a larger group of consumer health care units.

Johnson & Johnson said the changes will allow it to “give focused attention to quality and compliance, and the critical task of restoring McNeil Consumer Healthcare brands.”

The New Brunswick, N.J., company said Pat Mutchler will be in charge of the McNeil business. He will also lead other division and the company’s joint venture with Merck & Co.

Millions of bottles of McNeil products have been recalled since September 2009. The New Brunswick, N.J., company said those problems cost it $900 million in sales in 2010.